JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 33 No. 2 277-281
© 1992 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howell, R. W.
Right arrow Articles by Rao, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howell, R. W.
Right arrow Articles by Rao, D. V.

Absorbed Dose Calculations for Rapidly Growing Tumors

Roger W. Howell, Venkat R. Narra and Dandamudi V. Rao

Department of Radiology, Division of Radiation Research, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103

Correspondence: For reprints contact: Roger W. Howell, PhD, Department of Radiology, MSB F-451, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103.

ABSTRACT

One of the most promising areas for cancer therapy with administered radiopharmaceuticals is the treatment of very small tumors and micrometastases. Small tumors and micrometastases, however, may be rapidly growing at the time of treatment, resulting in a substantial change in mass during the period of irradiation. In this work, the formalism required to calculate the average absorbed dose to rapidly growing tumors is developed and applied to an in vitro tumor model. Further application to in vivo human myeloma tumors reveals that tumor growth may have a significant effect on the average dose delivered to the tumor from incorporated radionuclides. These considerations may assist in establishing dose-response relationships necessary for radiopharmaceutical cancer therapy.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. Hindorf, O. Linden, L. Stenberg, J. Tennvall, and S.-E. Strand
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients
Clin. Cancer Res., September 1, 2003; 9(10): 4003S - 4006.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. L. Thakur, R. Coss, R. Howell, D. Vassileva-Belnikolovska, J. Liu, S. P. Rao, G. Spana, P. Wachsberger, and D. L. Leeper
Role of Lipid-Soluble Complexes in Targeted Tumor Therapy
J. Nucl. Med., August 1, 2003; 44(8): 1293 - 1300.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1992 by the Society of Nuclear Medicine.